SPRO

$1.04+0.00%visit website

Spero Therapeutics, Inc.

Market Cap

$61M

Live price × SEC shares (Aug 7, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.55

60mo monthly vs SPY

P/E (TTM)

7.4

TTM to Jun 2026 · diluted EPS

P/S (TTM)

1.3

TTM to Jun 2026 · revenue

P/B

1.4

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	5,442	41,297	258	0	46,997
Research & development	8,597	5,592	2,909	3,434	20,532
Total operating expenses	13,358	9,892	7,796	9,926	40,972
Operating income	(7,916)	31,405	(7,538)	(9,926)	6,025
Income tax	0	261
Net income	(7,382)	31,520	(7,203)	(9,552)	7,383
EPS (basic) ($)	(0.13)		(0.13)	(0.16)	0.14
EPS (diluted) ($)	(0.13)		(0.13)	(0.16)	0.14
Weighted avg. shares (basic)	56,281		57,282	57,969
Weighted avg. shares (diluted)	56,281		57,282	57,969

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 12, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 38 more quarters, back to Mar 2016, with Tormere Pro.

Corporate Events (8-K)

1 filing in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 27, 2026 accepted 5:16 PM ET	5.02Officer / director change	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

42%

W/W +6.3pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-05-04	2026-05-06	Rajavelu Esther	See Remarks	Sale	25.2K	$2.51	$63K	986.9K	View
2026-02-06	2026-02-09	Rajavelu Esther	See Remarks	Sale	87.9K	$2.36	$207K	1.01M	View
2026-02-06	2026-02-09	Keutzer Timothy	Chief Operating Officer	Sale	18.7K	$2.36	$44K	742.5K	View
2026-02-02	2026-02-04	Rajavelu Esther	See Remarks	Sale	18.4K	$2.20	$41K	1.10M	View
2025-11-07	2025-11-12	Rajavelu Esther	See Remarks	Sale	40.3K	$2.37	$95K	869.5K	View

Recent News

Spero Therapeutics to Present at Investor Conferences in November

Yahoo · 2026-11-02

Spero CEO Esther Rajavelu will join a Boston healthcare conference for a fireside chat.

Stock Titan · 2026-11-02

Spero Therapeutics(SPRO) Stock Options Chain | Quotes & News

Moomoo · 2026-10-31

Spero Therapeutics Stock Price Forecast. Should You Buy SPRO?

StockInvest.us · 2026-10-30

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday

Benzinga · 2026-10-29

This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Benzinga · 2026-10-28

Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces Price Target of $6

Benzinga · 2026-10-28

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

Yahoo · 2026-10-26

Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease

Yahoo · 2026-10-21

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Yahoo · 2026-10-15

Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight

Yahoo · 2026-10-12

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo Finance · 2026-10-02

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Yahoo Finance · 2026-09-03

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Yahoo Finance · 2026-09-02

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

Yahoo Finance · 2026-08-19

Informational purposes only, not investment advice.

SPRO

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

Spero Therapeutics, Inc. (SPRO)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-05-04	Rajavelu Esther	S	25,240	$63,352.4
2026-02-06	Rajavelu Esther	S	37,101	$87,558.36
2026-02-06	Rajavelu Esther	S	50,816	$119,925.76
2026-02-06	Keutzer Timothy	S	18,652	$44,018.72
2026-02-02	Rajavelu Esther	S	18,442	$40,572.4